TransCode Therapeutics has reported promising findings with its primary therapeutic candidate, TTX-MC138, in non-human primates. The study demonstrated that TTX-MC138 effectively engaged its target, showcased favorable pharmacokinetics, and exhibited desirable tissue distribution.
Successful Imaging Study Conducted on Non-Human Primates
In order to determine the pharmacokinetics and tissue distribution of TTX-MC138, the study involved injecting non-human primates with a microdose of radio-labeled TTX-MC138. The subjects were then imaged using positron emission tomography-magnetic resonance imaging.
Positive Findings Encouraging for Prospects in Cancer Treatment
Results from the study indicated that TTX-MC138 displayed a prolonged circulation half-life and exhibited tissue distribution consistent with hepatic clearance. Even at a microdose, the therapeutic demonstrated enduring activity and effectively inhibited miRNA-10b, which is known to drive metastatic progression in various cancers.
These encouraging findings have led TransCode to believe that TTX-MC138 holds potential as a treatment for certain types of cancer. Furthermore, the administration of TTX-MC138 has led to complete regression of metastatic disease in mouse models of both pancreatic and breast cancer. Additionally, a case study involving spontaneous feline mammary carcinoma demonstrated successful delivery and preliminary efficacy of TTX-MC138.
Following the announcement, shares of TransCode experienced a 13% increase in premarket trading, reaching $2.61 per share.